

1 **Title:** Protocol for a prospective, hospital-based registry of pregnant women with SARS-CoV-2  
2 infection in India: PregCovid Registry study

3 **Authors**

4 Rahul K Gajbhiye, MBBS, PhD<sup>1\*</sup>,

5 Niraj N Mahajan, MD<sup>2</sup>,

6 Rakesh Waghmare, MD<sup>3,4</sup>,

7 Suchitra Surve, MBBS, DCH<sup>1</sup>,

8 Prashant Howal, MD<sup>4</sup>,

9 Aishwarya Bhurke, MSc<sup>1</sup>,

10 Merlin Pious, MSc<sup>1</sup>,

11 Deepak N Modi, PhD<sup>5</sup>,

12 Smita D Mahale, PhD<sup>6#</sup>

13 **Author affiliations**

14 <sup>1</sup>Clinical Research Lab, ICMR-National Institute for Research in Reproductive Health, Mumbai,  
15 India

16 <sup>2</sup>Department of Obstetrics & Gynecology, Topiwala National Medical College & BYL Nair  
17 Charitable Hospital, Mumbai India

18 <sup>3</sup>Medical Education and Drugs Department, Government of Maharashtra, India

19 <sup>4</sup>Department of Community Medicine, Grant Government Medical College, and Sir J. J. Group  
20 of Hospitals, Mumbai, India

21 <sup>5</sup>Molecular and Cellular Biology Laboratory, ICMR-National Institute for Research in  
22 Reproductive Health, J M Street, Parel, Mumbai

23 <sup>6</sup>Structural Biology Department, ICMR-National Institute for Research in Reproductive Health,

24 J M Street, Parel, Mumbai, India

25 # superannuated

26 **Corresponding Author:**

27 Dr. Rahul Gajbhiye (0000-0003-3864-1818)

28 Scientist D & DBT Wellcome India Alliance

29 Clinical & Public Health Intermediate Fellow,

30 Clinical Research Lab,

31 ICMR-National Institute for Research in Reproductive Health,

32 Parel, Mumbai, 400012, INDIA

33 Telephone: +91 22 24192036

34 Email: [gajbhiyer@nirrh.res.in](mailto:gajbhiyer@nirrh.res.in)

35 **ABSTRACT**

36 **Introduction:** Pregnant women are at increased risk of contracting coronavirus disease 2019  
37 (COVID-19) due to several factors and therefore require special attention. However, the  
38 consequences of the COVID-19 pandemic on pregnant women and their newborns remain  
39 uncharted. The PregCovid registry aims to document the impact of SARS-CoV-2 infection on  
40 pregnant, post-partum women and their newborns. The aim of the registry is also to determine  
41 mother-to-child transmission of SARS-CoV-2 infection in India.

42 **Methods and analysis:** PregCovid is a hospital-based registry for capturing information of  
43 pregnant, post-partum women with COVID-19 and their newborns in India. Medical case

44 records of pregnant and post-partum women with laboratory-confirmed diagnoses of COVID-19  
45 will be captured in real-time using an online electronic patient record (EPR) software. The  
46 frequency of each symptom will be calculated. The laboratory data will be analyzed for  
47 calculating the frequency of laboratory parameters consistently higher in women with COVID-  
48 19. The adverse pregnancy and neonatal outcomes will be analyzed and their frequency will be  
49 calculated. Response to treatment will be analyzed for frequency calculation (number of women  
50 treated with different treatment regimens). The mother-to-child transmission data will be  
51 analyzed from the RT-PCR and/ antibody data of neonatal and maternal samples tested wherever  
52 the information is available. The registry data will be crucial for developing strategies for  
53 reducing the adverse impact of COVID-19 on pregnant women and their new-born.

54 **Ethics and dissemination:** The study is approved by the Institutional Ethics Committee of  
55 ICMR-National Institute for Research in Reproductive Health (#55/2020), BYL Nair Hospital,  
56 Mumbai, India (# 63/2020); and all the 18 participating study sites under Medical Education and  
57 Drugs Department of Government of Maharashtra. The Institutional Ethics Committees granted  
58 a waiver of consent as the data is collected from the medical case records.

59 **Trial registration number:** CTRI/2020/05/025423

60 **Keywords:** COVID-19, Coronaviruses, New-born, Pregnancy, Registry, Viruses, Vertical  
61 transmission

62 **Article summary**

63 **Strengths and limitations of this study**

- 64 • The PregCovid registry is a hospital-based registry at dedicated COVID-19 hospitals in  
65 India. The registry will help to identify new epidemiological, clinical characteristics,  
66 obstetrics outcomes associated with pregnant women and/post-partum women with

67 COVID-19 in India. The study will also generate information on clinical presentations  
68 and outcomes of neonatal born to mothers with COVID-19 in India.

69 • PregCovid registry will provide evidence of mother to child transmission of SARS-CoV-  
70 2 infection in Indian women

71 • The evidence on unusual presentations of COVID-19 in pregnant and post-partum  
72 women will be generated.

73 • The follow-up of participants is only till the discharge from the hospital. Long-term  
74 follow-up is not included in the study.

75

## 76 **Introduction**

77 Coronavirus disease 2019 (COVID-19) has emerged as a public health emergency with more  
78 than 103 million confirmed cases of COVID-19, including 2.3 million deaths, worldwide as [1].  
79 Several variants of SARS-CoV-2 are now emerging [2] however, it is still unknown whether  
80 they have any clinical impact on pregnant women. Several International and National agencies  
81 are actively engaged to address the impact of the COVID-19 pandemic. Previously, members of  
82 the coronavirus family such as severe acute respiratory syndrome coronavirus (SARS-Co-V) and  
83 Middle East Respiratory Syndrome (MERS-CoV) were reported to be associated with severe  
84 complications during pregnancy like miscarriage, fetal growth restriction, preterm birth, and  
85 maternal deaths [3]. In general, pregnant women are a vulnerable population and need special  
86 attention. Pregnant women are particularly susceptible to respiratory pathogens and severe  
87 pneumonia, due to various factors such as physiologic changes in the immune and  
88 cardiopulmonary systems (e.g. diaphragm elevation, increased oxygen consumption, and edema  
89 of respiratory tract mucosa) which make them at risk of hypoxia [4]. Since the initial period of  
90 reporting case reports or case series on pregnant women with COVID-19 from China, now there  
91 are several studies published from different geographical regions. Initial studies mainly from  
92 China reported that clinical presentation of pregnant women with COVID-19 was comparable to  
93 non-pregnant cases and there was no risk of mother to child transmission of Severe acute  
94 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [5]. However, subsequently,  
95 studies were demonstrating the adverse impact of COVID-19 on both maternal and newborn  
96 health [4,6–9]. Evidence is gathering which suggests that there might be population biases in the  
97 susceptibility of COVID-19. Analysis of 427 pregnant women of the UK registry revealed that  
98 there might be racial differences in the severity of presentation and outcomes [7]. Also, a higher

99 incidence of maternal death due to COVID-19 is reported in some countries as compared to  
100 China or Europe [10]. Similarly, in the United States of America (USA), ethnic disparities in  
101 incidence and outcomes are also observed in non-pregnant populations with COVID-19, notably  
102 in the USA [11]. Factors such as social behavior, health-seeking behavior, comorbidities, and  
103 unknown genetic influences could be possible causes of differences in presentation and outcomes  
104 of COVID-19. This highlights a need for population-specific data of pregnant women, to gain an  
105 insight into social-epidemiological and clinical determinants of outcomes in COVID-19.

106 Currently, in India, the number of COVID-19 cases is on the rise. The Ministry of Health and  
107 Family Welfare (MoHFW), Government of India, reported 1,04,80,455 total confirmed cases  
108 with 1,54,703 deaths as of 4<sup>th</sup> February 2021 [12]. Out of these, Maharashtra state contributed  
109 19,43,335 cases with 51,169 deaths due to COVID-19 [12]. COVID-19 affected Indian states  
110 including Maharashtra which need special attention in planning the strategies for combating  
111 COVID-19, especially in the vulnerable population such as pregnant women. Our preliminary  
112 observations suggest that nearly 12% of pregnant women in Maharashtra State have SARS-CoV-  
113 2 infection and about 10% of these are symptomatic, highlighting the emergency nature of the  
114 situation [13]. Currently, there is no epidemiological, demographic, and clinical information on  
115 pregnant women with COVID-19 in India. Additionally, health outcomes of neonates born to  
116 COVID-19 mothers have not been documented in the Indian population.

117 To address the knowledge gaps, ICMR-National Institute for Research in Reproductive Health  
118 (NIRRH) has initiated a hospital-based pregnancy registry to capture socio-demographic, clinical  
119 presentations, treatment outcomes, obstetric and neonatal outcomes in Indian women with  
120 COVID-19. Herein, we describe the protocol and the characteristics of this registry.

121

## 122 **Aim of PregCovid study**

123 The following research questions will be addressed:

- 124 1. What are the clinical characteristics of pregnant and post-partum women who are  
125 diagnosed with SARS- CoV-2 infection?
- 126 2. What are the pregnancy outcomes in Indian women with SARS-CoV-2 infection?
- 127 3. How does the treatment of SARS- CoV-2 infection in pregnancy influence the outcomes  
128 for mother and infant?
- 129 4. Are there any ethnic or socioeconomic determinants of clinical presentations and  
130 outcomes of COVID-19 in pregnant women?

## 131 **Objectives**

132 The objectives of the study are: a) To understand the socio-demographic, clinical presentations,  
133 reproductive characteristics of pregnant and post-partum women diagnosed with SARS-CoV-2  
134 infection b) To determine the pregnancy and fetal outcomes in women with SARS-CoV-2  
135 infection and study the effect of treatment on pregnancy outcomes c) To evaluate the proportion  
136 of maternal to the fetal transmission of SARS-CoV-2 infection in pregnancy.

## 137 **Materials and methods**

138 The PregCovid registry is a prospective, hospital-based study designed to capture hospital data of  
139 pregnant and post-partum women with COVID-19 and their newborns.

## 140 **Identification of study sites for data capturing**

141 Since Maharashtra is a hotspot region for COVID-19, it was decided initially to launch the  
142 registry to capture the data in the state. Towards that, the Medical Education and Drugs  
143 Department (MEDD) Government of Maharashtra and Municipal Corporation of Greater

144 Mumbai (MCGM) were consulted, and primary data on COVID-19 and pregnant women were  
145 collected by a rapid survey.

#### 146 **Data collection instrument**

147 An *a priori* requirement of the registry was the development of the case record form. Towards  
148 this RG and DM carried out a situational analysis of the current evidence on the effectiveness  
149 and outcomes of COVID-19 on pregnant women [14]. Based on the outcomes of the systematic  
150 review of the baseline data of more than 400 women from different parts of the world and also  
151 reviewing the USA registry PRIORITY: Pregnancy Coronavirus Outcomes Registry [15], we  
152 shortlisted the key parameters about which the information should be collected.

153 In the next step, the case record form was independently reviewed by a team of gynecologists  
154 and pediatricians. Their inputs were recorded and the case record form was modified by a  
155 consensus. The modified case record form was circulated to the Investigators (Professor & Head,  
156 Obstetrics and Gynecology Departments, and Professor & Head Pediatrics/Neonatology  
157 Department) of the PregCovid Registry Network for further feedback and its feasibility as they  
158 have experience of treating the COVID-19 cases. RG coordinated with Investigators of the  
159 PregCovid Registry Network Hospitals for pilot testing of the case record form. Based on the  
160 feasibility and pilot testing, the case record form was modified and finalized by the consensus of  
161 investigators (Table 1).

#### 162 **Tools for real-time data capture**

163 To capture the real-time data, an online electronic patient record (EPR) software was developed  
164 by an outsourced team of experts. The developed software was first tested using dummy data by  
165 a team of obstetricians and pediatricians from the participating study sites. The time for data  
166 entry was recorded for obstetrics and pediatrics sections. Based on the inputs received from the



167 user team, the software was modified and pilot testing was carried out before the actual start of  
168 the data entered into the software.

### 169 **Approval from Institutional Review Boards (IRB)**

170 The study is approved by the Institutional Ethics Committee of ICMR-National Institute for  
171 Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020);  
172 and all the 18 participating study sites under Medical Education and Drugs Department of  
173 Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as  
174 the data is collected from the medical case records.

### 175 **CTRI Registration**

176 The study is registered with the Clinical Trials Registry, India (CTRI) and the registration  
177 number is CTRI/2020/05/025423.

### 178 **Characteristics of the PregCovid registry network and requirements of additional** 179 **participating centers**

180 The overall flow of the study protocol is outlined in Figure 1. The registry is presently initiated  
181 with 19 participating centers; it is open for all public and private COVID-19 hospitals all over  
182 India. A dedicated PregCovid portal for data entry (<http://app.pregcovid.com/login>) is developed  
183 along with a website for giving information about the registry for prospective collaborators,  
184 publications, and any breakthrough information related to the registry (<https://pregcovid.com/>).  
185 BYL Nair Hospital, Mumbai, a dedicated COVID-19 hospital was the first study site of  
186 PregCovid registry [16].

187 Maharashtra State is the second most populous state in India with 112,374,333 of which male  
188 and female are 58,243,056 and 54,131,277 respectively [17]. The first case of COVID-19 in  
189 Maharashtra State was detected in Pune on 9<sup>th</sup> March 2020 and since then Maharashtra is

190 harboring around 30% of the total cases of COVID-19 burden in India [18]. To respond to this  
191 public health emergency, phase 1 of the implementation of the registry will be carried out  
192 through the 19 participating centers within Maharashtra.

193 The registry is open to others who wish to become a part of this network. The approaching  
194 centers must contact the Coordinator or the Principal Investigator of the registry at ICMR-  
195 NIRRH. They will need to obtain approval from their Institutional Ethics Committee and sign a  
196 Memorandum of Agreement with ICMR-NIRRH, Mumbai. For further details, the centers can  
197 visit the PregCovid website (<https://pregcovid.com/for-covid19-hospitals/>).

### 198 **Timelines**

199 The registry will collect anonymized real-time data of pregnant women diagnosed with COVID-  
200 19 and admitted until May 2022. The date is extendable depending on the duration of the  
201 pandemic. Interim analysis may be conducted at the discretion of the investigators in  
202 consultation with other stakeholders. The final analysis will be done after collecting all the data.

### 203 **Study instruments**

204 The registry is implemented through an app-based Electronic Patient Record (EPR) which is  
205 shared with participating centers and the site Principal Investigator (PI) will be responsible for  
206 data entry. Software is developed for online real-time data entry. The data will be entered online  
207 in the EPR from the original medical records of pregnant and/post-partum women with  
208 confirmed COVID-19 infection admitted in COVID-19 hospitals.

### 209 **Case record form**

210 The case record form is designed to include socio-demographic, epidemiological, clinical  
211 presentations, laboratory investigations, past medical and surgical history, current pregnancy  
212 details, pregnancy complications, treatment details, and outcomes. New-born data collection tool

213 includes date and time of delivery, mode of delivery, birth weight, sex of infant, whether  
214 livebirth/stillbirth, diagnosis with COVID-19 infection (if any), morbidity, and mortality data  
215 (Table 1).

### 216 **Training for data entry, monitoring, and quality control**

217 The site PIs and their team will be provided online training for data entry, quality control  
218 measures, and accuracy. A training manual and a video of detailed instructions on the use of the  
219 software will be provided to all participating study sites. The site PI will ensure that the data is  
220 entered in a near real-time manner. The site PIs will monitor the entry of individual data and  
221 ensure its accuracy. The team at NIRRH will periodically review the data entered for gaps and  
222 discrepancies.

### 223 **Data management, Protection of Privacy & Confidentiality**

224 No information will be collected related to the identity of the study participants. The names of  
225 the COVID-19 patients will not be entered into any of the documents. None of the COVID-19  
226 patient's details revealing their identity will be used in any reports and publications arising from  
227 this study. The information as per the case record form will be captured electronically in a  
228 central database created, maintained, and regularly updated at ICMR-NIRRH. Data entry and  
229 data access will be independently controlled and held behind secure firewalls. Data collected  
230 from different study sites will be kept separately and only specific individuals within a research  
231 team will be able to access and edit the data. The quality of the electronic data will be regularly  
232 monitored by the PI and research team at ICMR-NIRRH.

### 233 **Statistical analysis**

234 The frequency of each symptom will be calculated. The laboratory data will be analyzed for  
235 calculating the frequency of laboratory parameters consistently higher in women with COVID-

236 19. The adverse pregnancy and neonatal outcomes will be analyzed and their frequency will be  
237 calculated. Response to treatment will be analyzed for frequency calculation (number of women  
238 treated with different treatment regimens). The mother-to-child transmission data will be  
239 analyzed from the RT-PCR and/ antibody data of neonatal and maternal samples tested wherever  
240 the information is available. Data pooling and statistical analysis will be carried out using MS  
241 Excel and SPSS version 26 (SPSS South Asia Pvt. Ltd., Bangalore, India).

#### 242 **Patient and public involvement**

243 No patients or public were involved in the study design, conduct or reporting of our analysis.

#### 244 **Discussion**

245 To the best of our knowledge, this is the first registry on pregnant women with COVID-19 in  
246 India for capturing data on clinical presentation, obstetrics and neonatal outcomes, response to  
247 treatment, and mother to child transmission of SARS-CoV-2 infection. While the initial focus is  
248 on Maharashtra, as the pandemic unfolds, we anticipate having membership from different states  
249 representative of the Indian population. In its present form, it is geared to generate data of the  
250 worst affected state in India in a very systematic manner and its interim analysis would help  
251 other states to plan their strategies well in advance to manage pregnant women infected with  
252 SARS-CoV-2.

253 The study will also generate information on the ethnic and socio-demographic determinants of  
254 the clinical presentation, and outcomes of pregnant women with COVID-19. Together, this data  
255 will aid in planning the strategies to handle the epidemic of COVID-19 and pregnancy. This  
256 data is extremely important to develop rational management strategies for protecting pregnant  
257 women against possible adverse effects of COVID-19. This information will be also of

258 importance not just for COVID-19 but also provide a broad framework to deal with an entire  
259 group of coronaviruses that lead to common respiratory infections in general.

260 The preliminary findings of the registry data are useful for improved management of pregnancy  
261 with COVID-19. ICMR recommends universal testing of pregnant women in India. Accordingly,  
262 women residing in clusters/containment areas or large migration gatherings/evacuees centers  
263 from hotspot districts in India and presenting in labor or likely to deliver in the next 5 days were  
264 recommended to be screened for SARS-CoV-2 [19]. We observed a 12 % prevalence of SARS-  
265 CoV-2 in pregnant women with the presence of one symptomatic to every nine asymptomatic  
266 pregnant women [13]. These findings of the universal testing strategy of pregnant women are  
267 useful for planning strategies to prevent the spread of the virus to newborns, healthcare workers,  
268 and others in the community. The study also highlights that pregnant women should be paying  
269 special attention to their health. The significance of detecting asymptomatic pregnant women is  
270 useful for ensuring safe obstetric and neonatal services and assessing the burden of COVID-19 in  
271 the region to plan strategies on strengthening or relaxing mass physical distancing measures.

272 Detection of dengue and malaria coinfection with COVID-19 in pregnant women is useful for  
273 formulating the strategies for pregnant women living in malaria and dengue-endemic zones [20].  
274 Considering the COVID-19 reaching the tribal and rural parts of India, both public and private  
275 healthcare systems should be strengthened for diagnosis and appropriate management of co-  
276 infections. Documentation of post-partum psychosis in mothers with COVID-19 [21] is useful  
277 for creating awareness and providing appropriate mental health care for pregnant and postpartum  
278 women with COVID-19.

279 Globally, there are several National, Regional and International registries being established for  
280 pregnant women with COVID-19[22]. The objectives and the protocol of the PregCovid registry

281 are at par with these international registries and will open up an opportunity at the international  
282 level for data comparison and assimilation. Eventually, collaborations with an international  
283 consortium with global experts having experience in managing COVID-19 pregnant women  
284 would be useful for developing a global strategy on COVID-19 in pregnancy.

## 285 **Publication plan**

286 Publications will be submitted to international peer-reviewed journals on findings emerged from  
287 the data of the PregCovid study. Press releases and articles for lay audiences will also be  
288 prepared for important findings.

## 289 **Abbreviations**

290 COVID-19: Coronavirus disease 2019

291 CTRI: Clinical Trial Registry of India

292 EPR : Electronic patient record

293 IRB : Institutional Review Boards

294 MEDD : Medical Education and Drugs Department

295 MCGM : Municipal Corporation of Greater Mumbai

296 MERS-CoV : Middle East Respiratory Syndrome

297 MoHFW: Ministry of Health and family Welfare

298 PRIORITY: Pregnancy Coronavirus Outcomes Registry

299 SARS-CoV : Severe acute respiratory syndrome coronavirus

300 SARS-CoV-2 : Severe acute respiratory syndrome coronavirus 2

## 301 **Acknowledgments**

302 The authors sincerely acknowledge the support of the Director-General, Indian Council of  
303 Medical Research. Secretary, Medical Education, and Drugs Department; Director, Medical  
304 Education, and Drugs Department, Maharashtra; Dean, TNMC, Mumbai & BYL Nair Hospital;  
305 are acknowledged. Dr. Vandana Bansal, Dr. Dipti Tandon, Dr. Anushree Patil, Dr. Sudha Rao,  
306 Dr. Shakuntala Prabhu, Dr. Pooja Bandekar are sincerely acknowledged. All the Site  
307 Investigators and faculty, residents, interns working in the Departments of Obstetrics &  
308 Gynecology; Pediatrics and Neonatology of the network of the National Registry of Pregnant  
309 women with COVID-19 in India are sincerely acknowledged (PregCovid Registry,  
310 CTRI/2020/05/025423).

### 311 **Ethics approval and consent to participate**

312 The study is approved by the Institutional Ethics Committee of ICMR-National Institute for  
313 Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020);  
314 and all the 18 participating study sites under Medical Education and Drugs Department of  
315 Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as  
316 the data is collected from the medical case records.

### 317 **Data availability**

318 Data sharing is not applicable as no datasets were generated and/or analyzed for this study.

### 319 **Funding**

320 PregCovid registry is supported by an intramural grant of ICMR-NIRRH (ICMR-  
321 NIRRH/RA/965/09/2020). Rahul K Gajbhiye is an awardee of the DBT Wellcome India alliance  
322 clinical and public health intermediate fellowship (Grant no. IA/CPHI/18/1/503933).

### 323 **Authors' contributions**

- 324 Concept and design: RG
- 325 Development and validation of data collection instrument: RG, NM, RW, SS,
- 326 Pilot testing & validation of software: NM, AB, MP, RW, PH
- 327 Development of Training manual, online training: NM, AB, MP, RG, RW
- 328 Drafting of the manuscript: RG, NM, DM, SM
- 329 Critical revision of the manuscript for important intellectual content: All authors
- 330 Administrative and technical support: RG, RW, NM, SM
- 331 **Competing Interest**
- 332 There are no competing interests for any author.



## 333 **References**

- 334 1 Coronavirus disease (COVID-19) – World Health Organization.  
335 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (accessed 4 Feb 2021).
- 336 2 Burki T. Understanding variants of SARS-CoV-2. *The Lancet* 2021;**397**:462.  
337 doi:10.1016/S0140-6736(21)00298-1
- 338 3 Diriba K, Awulachew E, Getu E. The effect of coronavirus infection (SARS-CoV-2, MERS-  
339 CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal  
340 transmission: a systematic review and meta-analysis. *Eur J Med Res* 2020;**25**:39–39.  
341 doi:10.1186/s40001-020-00439-w
- 342 4 Yan J, Guo J, Fan C, *et al.* Coronavirus disease 2019 (COVID-19) in pregnant women: A  
343 report based on 116 cases. *American Journal of Obstetrics & Gynecology* 2020;**0**.  
344 doi:10.1016/j.ajog.2020.04.014
- 345 5 Chen H, Guo J, Wang C, *et al.* Clinical characteristics and intrauterine vertical transmission  
346 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical  
347 records. *The Lancet* 2020;**395**:809–15. doi:10.1016/S0140-6736(20)30360-3
- 348 6 Chen L, Li Q, Zheng D, *et al.* Clinical Characteristics of Pregnant Women with Covid-19 in  
349 Wuhan, China. *New England Journal of Medicine* 2020;**0**:null. doi:10.1056/NEJMc2009226
- 350 7 Knight M, Bunch K, Vousden N, *et al.* Characteristics and outcomes of pregnant women  
351 admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population  
352 based cohort study. *BMJ* 2020;**369**:m2107. doi:10.1136/bmj.m2107
- 353 8 Kayem G, Lecarpentier E, Deruelle P, *et al.* A snapshot of the Covid-19 pandemic among  
354 pregnant women in France. *J Gynecol Obstet Hum Reprod* 2020;**49**:101826.  
355 doi:10.1016/j.jogoh.2020.101826
- 356 9 Ellington S, Strid P, Tong VT, *et al.* Characteristics of Women of Reproductive Age with  
357 Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States,  
358 January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:769–75.  
359 doi:10.15585/mmwr.mm6925a1
- 360 10 Takemoto MLS, Menezes M de O, Andreucci CB, *et al.* The tragedy of COVID-19 in Brazil:  
361 124 maternal deaths and counting. *Int J Gynaecol Obstet* Published Online First: 9 July  
362 2020. doi:10.1002/ijgo.13300
- 363 11 Onwuzurike C, Diouf K, Meadows AR, *et al.* Racial and ethnic disparities in severity of  
364 COVID-19 disease in pregnancy in the United States. *Int J Gynaecol Obstet* Published  
365 Online First: 31 July 2020. doi:10.1002/ijgo.13333
- 366 12 MoHFW | Home. <https://www.mohfw.gov.in/> (accessed 4 Feb 2021).

- 367 13 Waghmare R, Gajbhiye R, Mahajan N, *et al.* Universal screening identifies asymptomatic  
368 carriers of SARS-CoV-2 among pregnant women in India. *European Journal of Obstetrics*  
369 *and Gynecology and Reproductive Biology* doi:10.1016/j.ejogrb.2020.09.030
- 370 14 Gajbhiye R, Modi D, Mahale S. Pregnancy outcomes, Newborn complications and Maternal-  
371 Fetal Transmission of SARS-CoV-2 in women with COVID-19: A systematic review.  
372 *medRxiv* 2020;:2020.04.11.20062356. doi:10.1101/2020.04.11.20062356
- 373 15 PRIORITY: Pregnancy Coronavirus Outcomes Registry. PRIORITY Study.  
374 <https://priority.ucsf.edu/home> (accessed 28 Aug 2020).
- 375 16 Mahajan NN, Pednekar R, Patil SR, *et al.* Preparedness, administrative challenges for  
376 establishing obstetric services, and experience of delivering over 400 women at a tertiary  
377 care COVID-19 hospital in India. *International Journal of Gynecology & Obstetrics*.  
378 2020.<https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13338> (accessed 25 Aug  
379 2020).
- 380 17 Census of India: Maharashtra Vol1.  
381 <https://censusindia.gov.in/2011census/maps/atlas/Maharashtra1.html> (accessed 28 Aug  
382 2020).
- 383 18 MEDD MARATHI 28 AUGUST 2020 REPORT.pdf. Google Docs.  
384 [https://drive.google.com/file/d/1IC5mgcrmFO8cLaCy4NY1DtUCbGupCGNL/view?usp=sha](https://drive.google.com/file/d/1IC5mgcrmFO8cLaCy4NY1DtUCbGupCGNL/view?usp=sharing&usp=embed_facebook)  
385 [ring&usp=embed\\_facebook](https://drive.google.com/file/d/1IC5mgcrmFO8cLaCy4NY1DtUCbGupCGNL/view?usp=sharing&usp=embed_facebook) (accessed 28 Aug 2020).
- 386 19 INDIAN COUNCIL OF MEDICAL RESEARCH, DEPARTMENT OF HEALTH  
387 RESEARCH. Strategy for COVID19 testing for pregnant women in India (Version 1, dated  
388 20/04/2020).  
389 2020.[https://www.icmr.gov.in/pdf/covid/strategy/COVID19\\_Testing\\_Strategy\\_for\\_Pregnant](https://www.icmr.gov.in/pdf/covid/strategy/COVID19_Testing_Strategy_for_Pregnant_Women.pdf)  
390 [\\_Women.pdf](https://www.icmr.gov.in/pdf/covid/strategy/COVID19_Testing_Strategy_for_Pregnant_Women.pdf)
- 391 20 Mahajan NN, Kesarwani SN, Shinde SS, *et al.* Co-infection of malaria and dengue in  
392 pregnant women with SARS-CoV-2. *International Journal of Gynecology & Obstetrics*.  
393 2020.<https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13415> (accessed 19 Oct  
394 2020).
- 395 21 Subramanyam AA, Nachane HB, Mahajan NN, *et al.* Postpartum psychosis in mothers with  
396 SARS-CoV-2 infection: A case series from India. *Asian Journal of Psychiatry* 2020;:102406.  
397 doi:10.1016/j.ajp.2020.102406
- 398 22 Covid-19 & pregnancy – registries. Ripe-tomato.org. 2020.[https://ripe-](https://ripe-tomato.org/2020/04/19/covid-19-pregnancy-registries/)  
399 [tomato.org/2020/04/19/covid-19-pregnancy-registries/](https://ripe-tomato.org/2020/04/19/covid-19-pregnancy-registries/) (accessed 23 Jul 2020).

400

401

402

403 **Table 1:** Maternal and New-born information concerning different parameters captured by  
 404 Electronic Patient Record for PregCovid registry

Maternal Information	Parameters
<b>Socio-Demographic and Epidemiological data</b>	Age, Religion, Occupation, Education, Financial status, Residential area (Red zone, Orange, Green)
<b>Medical History</b>	Anemia, Diabetes Mellitus, Chronic Hypertension, Blood disorders, Chronic obstructive disease, Asthma, Tuberculosis, Cardiac disorders, Psychiatric disorders, Thyroid disorders, Kidney disorder, rheumatoid arthritis, malignancy, Immunocompromised state, Previous surgical history, H/o contact in the community, exposure while caring for COVID-19 patient and foreign travel
<b>Obstetric History</b>	Gestational Age, and conception history, Gravida, Parity, Mode of delivery, Living Children, Abortions, Stillbirth, Ectopic Pregnancy, Molar Pregnancy, Preterm Birth
<b>Clinical Presentation of COVID-19</b>	Asymptomatic or Symptomatic, details of symptoms, Duration of symptoms, Intervals–symptoms onset to admission, Exposure/contact to diagnosis, Atypical Symptoms, Complications of COVID-19 (ARDS, Consolidation, Heart Failure, Septic Shock, Acute Renal Injury, etc.)
<b>General Physical Examination</b>	BMI, Stability of vitals, Oxygen Saturation at time of Admission, Lowest Oxygen saturation during hospitalization, Date, and method of COVID-19 Testing, Type of sample for COVID-19 Testing, Indications of COVID-19 Testing, X-ray, CT scan, other Laboratory Investigations, Co-infections like Malaria, Dengue, etc
<b>Delivery Details</b>	<p><i>Pregnancy Outcomes:</i> Delivered (Singleton/Multifetal), Undelivered, Spontaneous Abortion, Stillbirth, Ectopic Pregnancy, MTP</p> <p><i>Delivery details:</i> Mode of delivery, Duration of labor, Induction, CS details, Complications</p> <p><i>Pregnancy Complications:</i> Preeclampsia, Eclampsia, Placenta Previa, Placenta Abruption, Uterine Rupture, Premature Rupture Of Membranes, Oligohydramnios, Polyhydramnios, Antepartum</p>

	Postpartum Hemorrhage, Gestational Hypertension, Gestational Diabetes/ Pregestational Diabetes Mellitus, Preterm Labour, Chorioamnionitis, Fetal Growth Restriction, Congenital Malformation, Hematoma, Surgical Site Infection
<b>Treatment</b>	Antibiotics, Antivirals, Hydroxychloroquine, Steroids, Heparin, High-flow nasal cannula oxygen therapy, NIV, any other treatment and outcomes, Hospital and ICU stay, Blood transfusion, Convalescent Plasma Therapy
<b>Newborn Information</b>	<b>Parameters</b>
<b>Basic demographic and clinical investigations</b>	Date of birth, 5 min APGAR score, Gender, Congenital anomalies, Birth Weight, Feeding Details, NICU admission, Neonatal Complications, Indications and duration of NICU admission, Vaccination details, Testing for COVID-19, Cord blood testing for COVID-19( if available), Laboratory Investigations, Treatment and outcomes.

405

406 *APGAR- Appearance, Pulse, Grimace, Activity, and Respiration, CS- Cesarean delivery, MTP-*  
 407 *Medical Termination of Pregnancy, NIV- Non-Invasive Ventilation*

408

409

410 **Figure Legends**

411 **Figure 1:** Flowchart showing details on data collection, quality control, data analysis to be used  
 412 for PregCovid Registry

413

414

415

